Immuno-Oncology | Specialty

Sipuleucel-T Soon Available to Patients in Europe and Beyond

March 3rd 2014

An immunotherapy drug for the treatment of prostate cancer, approved in the US in 2010, will soon be available in Europe.

Dr. McDermott on Targeting PD-1/PD-L1 in Kidney Cancer

February 28th 2014

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses the potential of targeting PD-1 or PD-L1 in patients with kidney cancer

Immune Checkpoint Blockade in Cancer: Inhibiting CTLA-4 and PD-1/PD-L1 With Monoclonal Antibodies

February 21st 2014

Inhibitory receptors such as anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) expressed on tumor-specific T cells lead to compromised activation and suppressed effector functions such as proliferation, cytokine secretion, and tumor cell lysis.

Dendritic Vaccine Improves Survival in Recurrent Glioblastoma

February 19th 2014

A personalized vaccine being tested as a therapy for recurrent glioblastoma multiforme (GBM) improved patient survival compared with standard treatments

Dr. Herbst on Immunotherapy Agents in Lung Cancer

February 13th 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the using immunotherapy agents to treat patients with lung cancer.

Anti-PD-1 Antibody MK-3475 Advances Into Multiple Tumor Types

February 7th 2014

Merck announced the signing of three separate clinical collaboration agreements to evaluate the potential of its investigational anti-PD-1 immunotherapy MK-3475 across multiple tumor types

PD-L1 Expression Independent Prognostic Indicator in mRCC

February 3rd 2014

High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.

Dr. Figlin Describes the Efficacy of AGS-003 in mRCC

February 1st 2014

Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)

Dr. Gomella Discusses New Data on Sipuleucel-T

January 31st 2014

Leonard Gomella, MD, from the Kimmel Cancer Center Network, Thomas Jefferson University Hospital, provides an update on the dendritic cell cancer vaccine sipuleucel-T in castration-resistant prostate cancer.

The Role of Anti-PD-L1 Immunotherapy in Cancer

January 29th 2014

Immunotherapy has become an increasingly appealing therapeutic strategy for patients with cancer, with many late-stage clinical trials demonstrating overall survival (OS) advantages in melanoma and castrationresistant prostate cancer.

NewLink Genetics Pursues Dual Cancer Immunotherapy Platforms

January 20th 2014

Harnessing multiple components of the immune system to fight cancer is the focus of NewLink Genetics' clinical pipeline.

Anti-PD-1 Antibody Pidilizumab Shows Promise in Diffuse Large B-Cell Lymphoma

January 17th 2014

The anti-PD-1 monoclonal antibody pidilizumab showed promising clinical activity and was safely administered to patients with diffuse large B-cell lymphoma after autologous hematopoietic stem-cell transplantation.

Dr. John Marshall Provides Colorectal Cancer Updates

January 17th 2014

John L. Marshall, MD, from Georgetown University Hospital, on the recent advancements in colorectal cancer.

Studies Demonstrate Potential of Immunomodulation as Therapeutic Target in Gynecologic Cancers

January 17th 2014

The renaissance in immunology is already affecting treatment paradigms for a variety of gynecologic cancers, and the impact is only likely to expand.

Kris Provides Insight Into New Drugs for Lung Cancer

January 16th 2014

Mark G. Kris, MD, from the Memorial Sloan-Kettering Cancer Center, describes the new drugs and other emerging trends in lung cancer.

Dr. Piperdi on Immunotherapy in Lung Cancer

January 15th 2014

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the potential of immunotherapy for the treatment of patients with lung cancer.

Combined Vaccines Improve Survival in Metastatic Pancreatic Cancer

January 14th 2014

Combining two specific anti-cancer vaccines, rather than administering one as monotherapy, doubles the 1-year survival probability in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of a phase II study presented January 14.

Tasquinimod Improves OS, PFS in CRPC, Data Show

January 9th 2014

Tasquinimod, an experimental immunotherapy and anti-angiogenic agent, prolongs not just progression-free survival (PFS) but also overall survival (OS) in certain men with castration-resistant prostate cancer

Dr. Rizvi on Pseudo-Progression in Lung Cancer

January 6th 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.

Dr. Kluger on the Challenges of Treating Melanoma

January 2nd 2014

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the changes and challenges of treating patients with melanoma.